ALLO Allogene Therapeutics Inc

$ALLO Fear and loathing for weeks. Yet, we may be on the precipice of seeing beauty for ashes, dancing for mourning, strength for fear. Ultimately, let's get a good product out there that may help a lot of people in their fight against cancer.

$ALLO Finally trading under cash again. Gonna start increasing my position. Same as the last time this happened

$ALLO The more you look at this exceptional SSc patient from the ALLO-329 RESOLUTION trial abstract 1178 from ACR Convergence 2026, the more important the result becomes. This was progressive, treatment-refractory diffuse systemic sclerosis - a serious, high-mortality autoimmune disease - yet at only 40M ALLO-329 cells + cyclophosphamide, her mRSS dropped from 19 to 6 in just 3 months. Every time you put this patient into the proper disease context, the result tells us something important. It is still early and we need more patients and follow-up, but a 13-point reduction in clinically assessed skin thickness in progressive dcSSc deserves attention. This is one of the hardest autoimmune diseases to treat. This graphic below puts that result into perspective.

$ALLO if 329 is positive then we go to 75. It could be a bargain of the century at 1.60. Keep moving down so I can buy more! With others failing Allo technology could be te real deal. With no ichans or CRS the big boys could be knocking on their doors if trials succeed!

$ALLO looking for a 50,000% return to break even, lol! I have faith in my Allo and the researchers!!

$ALLO Majority of market down, not just allo. I knew after the USA rate hike, small cap and non revenue companies will get hit..does it make sense? No, cause allo has no debt...market manipulation at its finest...so hedges can make millions. But its part if the game..

$ALLO Holy F$&$ this really went green on Friday? Breaks a string of 12 straight days red. Did 10M in volume. Hmm

$ALLO Will the LBAs publish on Monday? Last year the late breaking abstracts published at what would be next week on Monday. They published on Monday October 13th. If Allogene has a late breaking abstract it could show up as early as next week. Also, if an LBA actually does show up from Allogene next week, it would fit in with the silence. Have a great weekend Longs.

$ALLO ALLO-329, Autoimmune, Immune reset, No Chemo. Major disruption took place in the first 14 days in the exceptional SSc patient discussed in abstract 1178. The image below shows this disruption and then the values keep going down as time moves forward. Remember if those bad T helper cells have been dismantled, it will take about six months for that network to come back. That network should come back to a balanced system and be healthy. Note: If this was a CD19 only CAR-T therapy, persistence is required because the T-helper network gets starved out by the B cells being suppressed. ALLO-329 targets them immediately when infused into the body.

$ALLO Another LinkedIn post by #ALLO. I think the rate of posts goes up as the price tag goes down

$ALLO The most critical near-term catalyst for Allogene is its expansion autoimmune • ALLO-329 (RESOLUTION Trial Data Update): Allogene is scheduled to release a significant clinical and translational data update in Q4 2026 for its Phase 1 RESOLUTION basket trial. • What it is targeting: This trial evaluates ALLO-329, a next-generation dual-targeted (CD19/CD70) AlloCAR T product for severe autoimmune conditions including Systemic Lupus Erythematosus (SLE), myositis, and scleroderma. • Why it's crucial: The Q4 readout will detail multiple dose levels (including the 20 million and 40 million cell cohorts). It is heavily watched because it utilizes Allogene’s proprietary Dagger® technology, which is designed to selectively eliminate the patient's rejection-primed immune cells. If successful, it could drastically reduce or entirely eliminate the need for harsh chemotherapy-based lymphodepletion before cell infusion, making autoimmune CAR-T vastly safer and easier to tolerate.

$ALLO Technical selling from the recent Caribou panic has pushed the stock against book value floor, but the actual underlying data points to a massive disconnect ahead of the ACR Convergence conference on Nov 9. The preliminary Phase 1 RESOLUTION data for the ALLO-329 autoimmune platform is already live and fully verified on the official ACR medical abstract registry (Abstract #1178): • Safety Blueprint: 0% Dose-Limiting Toxicities (DLTs) across the initial 9 patients treated. • Mechanism Proof: Successful B-cell depletion was explicitly achieved in both lymphodepleted and completely non-lymphodepleted (chemo-free) cohorts via their Dagger® tech [1.21]. • Early Clinical Efficacy: A severe Scleroderma patient saw a massive mRSS skin thickness reduction from 19 at baseline down to 6 at Month

$ALLO 🔥 ALLO-329 ACR abstract is now public and the early data are VERY encouraging • 9 patients treated • No DLTs • Only 1 Grade-1 CRS • B-cell suppression demonstrated • Activity at low doses • Activity even without conventional cyclophosphamide lymphodepletion 🔥 Standout result: systemic-sclerosis patient mRSS 19 → 6 at Month 3. Several individual areas reached 0, including upper arm by Day 14 and foot by Day 28. This could be a major validation signal for Allogene’s Dagger platform and the potential for off-the-shelf CAR-T with reduced/no traditional lymphodepletion. 📅 ALLO-329 ACR pres: Nov 9 🔥 TPG overhang is also GONE. TPG sold its entire 18.7M-share position at $1.55 (~$29M). Zero shares remaining. Meanwhile, ALLO has ~$424M cash/investments and runway into Q1 2029. So we have: ✅ ALLO-329 clinical activity ✅ Clean safety so far ✅ Dagger differentiation ✅ Huge cash runway ✅ TPG selling pressure finished ✅ November catalyst ✅ ALPHA3 ahead ✅ Significant short interest

$ALLO for ALLO to be mentioned on FOX business I believe something is brewing. I bought more this morning I’ll keep adding in case it keep dropping

$ALLO Reminder: Earnings -which won't help short term - 10/29. Trading today on lower than average volume and reflective of technical not panic selling. Lower than avg selling more characteristic -imo- buying support rather than heavy high institutional dumping.

$ALLO Kevin Mahn was on the Schwab Network shilling for #ALLO again today. What's with this guy? Interview was on LinkedIn and ALLO liked it.... Hmmm

$ALLO Hehehe, I’ve got no more money left to average down! Stop! We desperately need some good news!

$ALLO I have been buying a little every day it goes down. I think their technology is disruptive

$ALLO volume is 20% above normal- not indicative of selling. Stock has triggered technical sell signals by breaching the short and term moving averages which trading algos pick up on as do momentum traders. We are in a perfect spot to get attacked as the next near term even is "earnings"aka update on cash burn. Not expecting AnYThing good until November 7. Manage expectations and go touch some grass.

$ALLO compared to others in the market, still expensive 400m market cap, don’t see the 1,2$ quote Most bios are moving between 50m mkt cap More room to lower